{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T03:38:56Z","timestamp":1791689936466,"version":"4.3.4"},"reference-count":21,"publisher":"Japanese Society of Internal Medicine","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,4,15]]},"DOI":"10.2169\/internalmedicine.0150-22","type":"journal-article","created":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T22:11:53Z","timestamp":1660083113000},"page":"1151-1155","source":"Crossref","is-referenced-by-count":4,"title":["Favorable Management of Repeated Serous Retinal Detachment with Continued Tumor Response in a Patient with Intrahepatic Cholangiocarcinoma during Treatment with Pemigatinib"],"prefix":"10.2169","volume":"62","author":[{"given":"Masanobu","family":"Yukutake","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Hiroshima City Asa Citizens Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Sekito","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hiroshima City Asa Citizens Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiko","family":"Yamakita","sequence":"additional","affiliation":[{"name":"Department of Cancer Genome & Clinical Oncology, Hiroshima City Asa Citizens Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Itakura","sequence":"additional","affiliation":[{"name":"Itakura Eye Clinic, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koki","family":"Kabu","sequence":"additional","affiliation":[{"name":"Medical Affairs, Incyte Biosciences Japan, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Nagata","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hiroshima City Asa Citizens Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Foundation for Promotion of Cancer Research. Cancer Statistics [Internet]. [cited 2022 Jun 14]. Available from: https:\/\/link.edgepilot.com\/s\/a4f5b12a\/72fR6eLA20GBxKTb0GUbOg?u=https:\/\/ganjoho.jp\/public\/qa_links\/report\/statistics\/pdf\/cancer_statistics_2021.pdf"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Nagino M, Hirano S, Yoshitomi H, et al. Clinical practice guidelines for the management of biliary tract cancers 2019: the 3rd English edition. J Hepatobiliary Pancreat Sci 28: 26-54, 2021.","DOI":"10.1002\/jhbp.870"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Lee S, Oh SY, Kim BG, et al. Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer. Am J Clin Oncol 32: 348-352, 2009.","DOI":"10.1097\/COC.0b013e31818c08ff"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Pino MS, Milella M, Gelibter A, et al. Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. Oncology 76: 254-261, 2009.","DOI":"10.1159\/000205388"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Sasaki T, Isayama H, Nakai Y, et al. Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine. Invest New Drugs 30: 708-713, 2012.","DOI":"10.1007\/s10637-010-9553-9"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Suzuki E, Ikeda M, Okusaka T, et al. A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer. Cancer Chemother Pharmacol 71: 1141-1146, 2013.","DOI":"10.1007\/s00280-013-2106-0"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kim RD, McDonough S, El-Khoueiry AB, et al. Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer. Eur J Cancer Oxf Engl 1990 130: 219-227, 2020.","DOI":"10.1016\/j.ejca.2020.01.026"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Arai Y, Totoki Y, Hosoda F, et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology 59: 1427-1434, 2014.","DOI":"10.1002\/hep.26890"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. Nat Genet 47: 1003-1010, 2015.","DOI":"10.1038\/ng.3375"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R. The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing. Clin Cancer Res 22: 259-267, 2016.","DOI":"10.1158\/1078-0432.CCR-14-3212"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Maruki Y, Morizane C, Arai Y, et al. Molecular detection and clinicopathological characteristics of advanced\/recurrent biliary tract carcinomas harboring the <i>FGFR2<\/i> rearrangements: a prospective observational study (PRELUDE Study). J Gastroenterol 56: 250-260, 2021.","DOI":"10.1007\/s00535-020-01735-2"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Li F, Peiris MN, Donoghue DJ. Functions of FGFR2 corrupted by translocations in intrahepatic cholangiocarcinoma. Cytokine Growth Factor Rev 52: 56-67, 2020.","DOI":"10.1016\/j.cytogfr.2019.12.005"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 21: 671-684, 2020.","DOI":"10.1016\/S1470-2045(20)30109-1"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Javle M, Roychowdhury S, Kelley RK, et al. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with <i>FGFR2<\/i> fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol 6: 803-815, 2021.","DOI":"10.1016\/S2468-1253(21)00196-5"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. van der Noll R, Leijen S, Neuteboom GHG, Beijnen JH, Schellens JHM. Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities. Cancer Treat Rev 39: 664-672, 2013.","DOI":"10.1016\/j.ctrv.2013.01.003"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Stamer WD, Bok D, Hu J, Jaffe GJ, McKay BS. Aquaporin-1 channels in human retinal pigment epithelium: role in transepithelial water movement. Invest Ophthalmol Vis Sci 44: 2803-2808, 2003.","DOI":"10.1167\/iovs.03-0001"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Jiang Q, Cao C, Lu S, et al. MEK\/ERK pathway mediates UVB-induced AQP1 downregulation and water permeability impairment in human retinal pigment epithelial cells. Int J Mol Med 23: 771-777, 2009.","DOI":"10.3892\/ijmm_00000191"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Bahleda R, Meric-Bernstam F, Goyal L, et al. Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors. Ann Oncol Off J Eur Soc Med Oncol 31: 1405-1412, 2020.","DOI":"10.1016\/j.annonc.2020.06.018"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Yamamoto N, Ryoo BY, Keam B, et al. A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid malignancies. Invest New Drugs 38: 445-456, 2020.","DOI":"10.1007\/s10637-019-00780-w"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Francis JH, Harding JJ, Schram AM, et al. Clinical and morphologic characteristics of fibroblast growth factor receptor inhibitor-associated retinopathy. JAMA Ophthalmol 139: 1126-1130, 2021.","DOI":"10.1001\/jamaophthalmol.2021.3331"},{"key":"21","unstructured":"21. Francis JH, Habib LA, Abramson DH, et al. Clinical and morphologic characteristics of MEK inhibitor-associated retinopathy: differences from central serous chorioretinopathy. Ophthalmology 124: 1788-1798, 2017."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/8\/62_0150-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T03:26:40Z","timestamp":1681529200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/8\/62_0150-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,15]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.0150-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,15]]},"article-number":"0150-22"}}